Dermira Inc (NASDAQ:DERM) Director David E. Cohen sold 600 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $28.87, for a total transaction of $17,322.00. Following the completion of the transaction, the director now directly owns 30,282 shares of the company’s stock, valued at $874,241.34. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Dermira Inc (NASDAQ DERM) traded down $0.56 during trading on Friday, hitting $27.80. 668,778 shares of the stock were exchanged, compared to its average volume of 748,351. Dermira Inc has a one year low of $21.35 and a one year high of $38.75. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68. The firm has a market cap of $1,170.00, a P/E ratio of -4.46 and a beta of 0.75.
Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.12) by ($0.09). Dermira had a negative return on equity of 41.22% and a negative net margin of 992.18%. analysts expect that Dermira Inc will post -7.36 earnings per share for the current year.
A number of equities analysts recently weighed in on the stock. BidaskClub raised shares of Dermira from a “hold” rating to a “buy” rating in a research note on Tuesday. Leerink Swann upped their target price on shares of Dermira from $42.00 to $48.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 17th. Cantor Fitzgerald set a $45.00 price objective on shares of Dermira and gave the stock a “buy” rating in a research note on Monday, January 15th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Guggenheim restated a “buy” rating and set a $30.00 price objective on shares of Dermira in a research note on Thursday, December 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Dermira has a consensus rating of “Buy” and an average price target of $42.17.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/02/dermira-inc-derm-director-david-e-cohen-sells-600-shares.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.